These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9588864)

  • 41. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40.
    Verhoef J; Gekker G; Erice A; Peterson PK; Balfour HH
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):715-21. PubMed ID: 1425730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
    Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC
    J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotoxins: a clinical review of their use in the treatment of malignancies.
    Hertler AA; Frankel AE
    J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF).
    Yamamoto N; Ushijima N; Koga Y
    J Med Virol; 2009 Jan; 81(1):16-26. PubMed ID: 19031451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ribosome-inactivating proteins: from toxins to useful proteins.
    Stirpe F
    Toxicon; 2013 Jun; 67():12-6. PubMed ID: 23462379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CD4-derivatives therapy of HIV carriers].
    Mizukami T; Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():327-33. PubMed ID: 8271399
    [No Abstract]   [Full Text] [Related]  

  • 49. The chronically infected cell as a target for the treatment of HIV infection and AIDS.
    Petteway SR; Lambert DM; Metcalf BW
    Trends Pharmacol Sci; 1991 Jan; 12(1):28-34. PubMed ID: 1672479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Status of CD4-Based Therapies for Prophylaxis and Treatment of HIV Infection.
    Sinclair JP; Shearer WT
    BioDrugs; 1997 Aug; 8(2):128-38. PubMed ID: 18020501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assays that measure selective killing of virus-infected cells.
    Randall S
    Methods Mol Med; 2000; 24():213-22. PubMed ID: 21331912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.
    Malecki M; Saetre B
    Mol Cell Ther; 2018; 6(1):. PubMed ID: 30931130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted toxin therapy for the treatment of cancer.
    FitzGerald D; Pastan I
    J Natl Cancer Inst; 1989 Oct; 81(19):1455-63. PubMed ID: 2550658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.
    Marsden MD; Xu J; Hamer D; Zack JA
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1399-404. PubMed ID: 19000022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Physiopathologic bases of anti-HIV therapy].
    Dormont D; Clayette P; Roques P
    Therapie; 1989; 44(6):385-92. PubMed ID: 2623652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential use of immunoconjugates for AIDS therapy.
    Kim YW; Chang TW
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1033-8. PubMed ID: 1503818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotoxins for targeted cancer therapy.
    Pastan I; Kreitman RJ
    Adv Drug Deliv Rev; 1998 Apr; 31(1-2):53-88. PubMed ID: 10837618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotoxins and central nervous system neoplasia.
    Hall WA; Fodstad O
    J Neurosurg; 1992 Jan; 76(1):1-12. PubMed ID: 1727147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective elimination of autoreactive lymphocytes with immunotoxins.
    Krolick KA
    Clin Immunol Immunopathol; 1989 Mar; 50(3):273-82. PubMed ID: 2645071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future of antiviral immunotoxins.
    Spiess K; Jakobsen MH; Kledal TN; Rosenkilde MM
    J Leukoc Biol; 2016 Jun; 99(6):911-25. PubMed ID: 26729815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.